Login
Emergent BioSolutions Inc NYSE: EBS
Emergent BioSolutions Inc. is a biopharmaceutical company that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Company develops, manufactures and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of biological and chemical threats and emerging infectious diseases (EID).
| Name | Emergent BioSolutions Inc |
| Ticker | EBS |
| Exchange | NYSE |
| Sector | Health Care |
| Industry | Drug Manufacturers - Diversified |
| Price | 106.29 |
| 52W Low/High | 49.34 / 134.94 |
| Market cap | 5.6 B |
| 1Y Total Return |
91.31%
Strong |
| 1Y Volatility |
70.04%
More Risk |
Emergent BioSolutions Inc. is a biopharmaceutical company that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Company develops, manufactures and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of biological and chemical threats and emerging infectious diseases (EID).
Details
| Ticker | EBS |
| Name | Emergent BioSolutions Inc |
| ISIN | US29089Q1058 |
| CUSIP | 29089Q105 |
| Exchange | NYSE |
| Sector | Health Care |
| Industry | Drug Manufacturers - Diversified |
| Country | USA |
| Currency | U.S. Dollar |
| In Index(ices) | US S&P Small Cap 600 |
Share as of 1/15/21
| Close Price | 106.29 |
| 52W Low/High | 49.34 / 134.94 |
| Market cap | 5.6 B |
| 1Y Total Return |
91.31%
Strong |
| 1Y Volatility |
70.04%
More Risk |
| Beta | 1.51 |
| PE (trailing) |
34.18
Above Average |
| 12M Dividends | - |
| Last Dividend Date | 8/1/16 |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | 12.5% |
| Cash from Op. / Cur. Liabilities | 1.38 |
| Diluted Earnings / Share | 3.11 |
| ROE | 14.6% |
| ROIC | -70.7% |
| Price / Revenue | 4.3 |
| Price / Book | 4.6 |
| Price / CF | 14.0 |
| Current Ratio | 3.2 |
| Cur.Liabilities / Tot.Liabilities | 0.2 |
| Financial Leverage | 0.70 |
| in Mils USD |
rolling-year up to September
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
1,333
|
1,016
|
705
|
519
|
497
|
450
|
|
| Gross Profit |
844
|
602
|
434
|
360
|
369
|
353
|
|
| R&D |
238
|
215
|
119
|
95
|
107
|
107
|
|
| EBITDA |
371
|
155
|
182
|
169
|
133
|
145
|
|
| Operating Income |
253
|
48
|
132
|
122
|
120
|
132
|
|
| Net Income exc. Extra |
167
|
4
|
100
|
86
|
48
|
60
|
|
| per Share | |||||||
| Diluted avg Shares |
54
|
52
|
52
|
50
|
49
|
48
|
|
| EPS exc. Extra |
3.11
|
0.07
|
1.97
|
1.79
|
1.00
|
1.25
|
|
| Dividend |
-
|
-
|
-
|
-
|
2.00
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
6.34%
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
2,616
|
2,334
|
1,174
|
1,024
|
932
|
977
|
|
| Cash, Eq & Invt ShortTerm |
415
|
139
|
340
|
342
|
299
|
309
|
|
| Total Current Assets |
959
|
700
|
563
|
556
|
480
|
473
|
|
| Total Non-Current Assets |
1,658
|
1,634
|
610
|
468
|
452
|
503
|
|
| Intangibles |
945
|
996
|
157
|
70
|
76
|
112
|
|
| Total Liabilities |
1,365
|
1,299
|
207
|
360
|
384
|
371
|
|
| Total Current Liabilities |
299
|
275
|
102
|
75
|
110
|
89
|
|
| Long Term Debt |
1,066
|
1,024
|
105
|
285
|
274
|
283
|
|
| Shareholder equity |
1,252
|
1,035
|
967
|
664
|
548
|
605
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
413
|
-100
|
285
|
118
|
68
|
93
|
|
| Depreciation |
114
|
108
|
50
|
40
|
38
|
34
|
|
| Cash from Investing |
-151
|
-909
|
-256
|
-62
|
-68
|
-51
|
|
| Capex |
141
|
72
|
64
|
62
|
67
|
50
|
|
| Cash from Financing |
14
|
808
|
-30
|
-13
|
-10
|
24
|
|
| Stock Issued |
29
|
10
|
-13
|
13
|
25
|
19
|
|
| Debt (LT) Issued |
47
|
808
|
0
|
-21
|
0
|
2
|
|
| Free Cash Flow |
-1,436
|
-52
|
71
|
-31
|
27
|
-92
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
12.5%
|
0.4%
|
14.2%
|
16.6%
|
9.6%
|
13.2%
|
|
| NCFO / Op.Income |
163.0%
|
-209.4%
|
216.5%
|
96.6%
|
57.1%
|
70.6%
|
|
| Current Ratio |
3.2
|
2.5
|
5.5
|
7.4
|
4.4
|
5.3
|
|
| Financial Leverage D/E |
0.70
|
0.80
|
0.01
|
0.38
|
0.49
|
0.42
|
|
| Return on Capital Avg |
-70.7%
|
3.4%
|
14.9%
|
13.8%
|
10.6%
|
-7.7%
|
|
| Return on Shareholder Equity |
14.6%
|
0.4%
|
12.3%
|
14.2%
|
8.3%
|
10.7%
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available